{
    "nctId": "NCT05226663",
    "briefTitle": "A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer",
    "officialTitle": "Imaging Using the Novel Radiotracer [18F] FluorThanaTrace([18F]FTT) by PET/CT in Patients With Breast Cancer",
    "overallStatus": "SUSPENDED",
    "conditions": "Breast Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 36,
    "primaryOutcomeMeasure": "Correlation of [18F]FluorThanatrace (FTT) uptake with PARP expression",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants will be \\>= 18 years of age\n* Known primary breast cancer. For subjects with primary breast cancer we will target lesion size of 1.0 cm or greater on at least one type of standard clinical imaging (e.g. mammogram, ultrasound, breast magnetic resonance imaging \\[MRI\\])\n* A candidate for primary breast surgery (mastectomy or lumpectomy)\n* Participants must be informed of the investigational nature of this study and provide written informed consent, in accordance with institutional and federal guidelines prior to study-specific procedures\n\nExclusion Criteria:\n\n* Females who are pregnant or breast feeding will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential prior to injection of FTT\n* Inability to tolerate imaging procedures in the opinion of an investigator or treating physician\n* Current or prior therapy for the primary breast cancer\n* Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}